Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6041 Combination Therapy for Recurrent Ovarian Cancer
NCT07714668Phase 2Recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6041 in ovarian cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Aug 2026; status: recruiting.
02
Drugs
SYS6041
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07714668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714668.